Skip to main content

Ilumya (Tildrakizumab) & Lymphoma

Basic Details
Status
Ongoing
Last Updated
Tuesday, November 19, 2024
Original Posting Date
Health Outcome(s)
lymphoma
Purpose
Drug and Outcome Analysis
Meets requirements of FD&C Act Sec 505(o) prior to requiring a PMR
Yes
Result(s) (3)
Follow-Up Time for Guselkumab, Risankizumab, and Tildrakizumab Users with Plaque Psoriasis: First Descriptive Analysis Utilization of Guselkumab, Risankizumab, Tildrakizumab, and Brodalumab: Second Descriptive Analysis Utilization of Guselkumab, Risankizumab, Tildrakizumab, and Brodalumab: Third Descriptive Analysis
Regulatory Link(s) (1)
FDA Approval Package Materials